☆ 4.7 Review

Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis

DIABETES OBESITY & METABOLISM (2022)

Related references

Note: Only part of the references are listed.

Review Virology

Obesity aggravates COVID-19: A systematic review and meta-analysis

Jun Yang et al.

Summary: The study found that severe COVID-19 patients tend to have a higher body mass index compared to non-severe patients, and COVID-19 patients with obesity have a worse outcome than those without, suggesting that obesity may exacerbate the effects of COVID-19.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

Martin Friedrichsen et al.

Summary: This study investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in adults with obesity. The results showed that semaglutide significantly suppressed appetite, improved control of eating, and reduced food cravings, ad libitum energy intake, and body weight compared to placebo. However, there was no evidence of delayed gastric emptying with semaglutide at week 20.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial

Thomas A. Wadden et al.

Summary: This study compared the effects of once-weekly subcutaneous semaglutide with placebo as an adjunct to intensive behavioral therapy and initial low-calorie diet for weight management in adults with overweight or obesity. The results showed that semaglutide led to significantly greater weight loss compared to placebo over 68 weeks, with a higher proportion of participants achieving weight loss goals. More research is needed to evaluate the long-term effectiveness of this treatment.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial

Melanie Davies et al.

Summary: In this study, once-weekly subcutaneous semaglutide 2.4 mg was shown to achieve a significantly greater and clinically meaningful weight reduction compared to placebo in adults with overweight or obesity and type 2 diabetes. Adverse events, particularly gastrointestinal events, were more common with semaglutide compared to placebo.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P. H. Wilding et al.

Summary: The study demonstrates that for individuals with obesity, once-weekly use of 2.4 mg semaglutide in combination with lifestyle intervention can lead to sustained and clinically relevant weight loss, with significant improvements in cardiometabolic risk factors and physical functioning reported by participants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial

Domenica Rubino et al.

Summary: Continuing treatment with semaglutide resulted in greater weight loss maintenance and improvement in other physical indicators compared to switching to placebo over a 48-week period in adults with overweight or obesity. The study also found that gastrointestinal events were more common with continued semaglutide, but discontinuation rates were similar between the two groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Endocrinology & Metabolism

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

Timotius Ivan Hariyanto et al.

Summary: The study suggests that pre-admission use of GLP-1RA may offer beneficial effects on Covid-19 mortality in patients with diabetes mellitus, but more randomized clinical trials are needed to confirm this conclusion.

DIABETES RESEARCH AND CLINICAL PRACTICE (2021)

Add to Collection

Article Medicine, General & Internal

Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18

Limin Wang et al.

LANCET (2021)

Add to Collection

Review Endocrinology & Metabolism

Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review

Nadia N. Ahmad et al.

Summary: Anti-obesity medications show effectiveness in real-world settings with weight loss and improvements in cardiometabolic risk factors, but there is limited evidence on their impact on obesity-related comorbidities and mortality. Adverse events are mild to moderate, and poor adherence and persistence with medications are common issues among patients. AOMs offer benefits but also have gaps in evidence.

OBESITY REVIEWS (2021)

Add to Collection

Article Endocrinology & Metabolism

Obesity in China 3 Health policy and public health implications of obesity in China

Youfa Wang et al.

Summary: China has experienced significant social, economic, and lifestyle changes since the 1990s, leading to a rise in obesity rates. Despite efforts to tackle obesity, the country still faces challenges in controlling the epidemic and the associated burden on the healthcare system. The Healthy China 2030 national strategy provides an opportunity for China to establish comprehensive national strategies for addressing obesity, but strong commitment and leadership from central and local governments, as well as active participation from all sectors of society, are needed.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide

Fabian Sanchis-Gomar et al.

MAYO CLINIC PROCEEDINGS (2020)

Add to Collection

Review Endocrinology & Metabolism

Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis

Panagiotis Andreadis et al.

DIABETES OBESITY & METABOLISM (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Patrick M. O'Neil et al.

LANCET (2018)

Add to Collection

Review Endocrinology & Metabolism

The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis

Xuejing Li et al.

ENDOCRINE (2018)

Add to Collection

Article Medicine, General & Internal

Health Effects of Overweight and Obesity in 195 Countries over 25 Years

Ashkan Afshin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Endocrinology & Metabolism

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

John Blundell et al.

DIABETES OBESITY & METABOLISM (2017)

Add to Collection

Article Endocrinology & Metabolism

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

W. Timothy Garvey et al.

ENDOCRINE PRACTICE (2016)

Add to Collection

Article Medicine, General & Internal

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Endocrinology & Metabolism

European Guidelines for Obesity Management in Adults

Volkan Yumuk et al.

OBESITY FACTS (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.